NCT06752681View on ClinicalTrials.gov

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Advanced or Metastatic Solid Tumors
Interventions
DRUG

DAY301

DAY301 will be administered as IV infusion

Trial Locations (12)

10021

RECRUITING

Site: 001-039, New York

32746

RECRUITING

Site: 001-063, Lake Mary

34232

RECRUITING

Site: 001-064, Sarasota

37203

RECRUITING

Site: 001-065, Nashville

46202

RECRUITING

Site: 001-060, Indianapolis

49546

RECRUITING

Site: 001-059, Grand Rapids

73104

RECRUITING

Site: 001-073, Oklahoma City

77030

RECRUITING

Site: 001-069, Houston

78229

RECRUITING

Site: 001-057, San Antonio

06510

RECRUITING

Site: 001-058, New Haven

V5Z 4E6

RECRUITING

Site: 011-013, Vancouver

M5G 2M9

RECRUITING

Site: 011-005, Toronto

Sponsors
All Listed Sponsors
lead

Day One Biopharmaceuticals, Inc.

INDUSTRY

NCT06752681 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter